Sorrento Therapeutics Inc (NASDAQ:SRNE)
| 1.45 Delayed Data As of May 24 |  -0.13 / -8.23%Today’s Change | 1.15 Today|||52-Week Range 11.07 | -68.82% Year-to-Date |
Latest SRNE News | Press Releases
| Kamada (KMDA) Reports Q1 Loss, Lags Revenue Estimates May 17 / Zacks.com - Paid Partner Content | Aravive (ARAV) Reports Q1 Loss, Tops Revenue Estimates May 12 / Zacks.com - Paid Partner Content |
| Albireo Pharma (ALBO) Reports Q1 Loss, Lags Revenue Estimates May 16 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 1.58 |
| Today’s open | 1.54 |
| Day’s range | 1.43 - 1.54 |
| Volume | 375,177 |
| Average volume (3 months) | 8,927,062 |
| Market cap | $618.4M |
Data as of 4:00pm ET, 05/24/2022
Growth & Valuation
| Earnings growth (last year) | -11.89% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +1.00% |
| Revenue growth (last year) | +32.31% |
| P/E ratio | NM |
| Price/Sales | 25.91 |
| Price/Book | 6.35 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CHRSCoherus BioSciences ... | -0.32 | -4.01% |
| QUREUniqure NV | +0.87 | +6.51% |
| SGMOSangamo Therapeutics... | -0.46 | -11.47% |
| ANABAnaptysBio Inc | -0.54 | -2.63% |
Data as of 4:00pm ET, 05/24/2022
Financials
| Last reporting date | May 25, 2022 |
| EPS forecast (this quarter) | -$0.17 |
| Annual revenue (last year) | $52.9M |
| Annual profit (last year) | -$428.3M |
| Net profit margin | -809.63% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
